LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease, today announced a strategic investment from Sarepta Therapeutics, Inc. (Sarepta) to support the advancement of LEXEO’s adeno-associated virus (AAV) gene therapy programs.
- NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease, today announced a strategic investment from Sarepta Therapeutics, Inc. (Sarepta) to support the advancement of LEXEO’s adeno-associated virus (AAV) gene therapy programs.
- In connection with this investment, the companies will explore the development of novel gene therapy candidates for a range of cardiovascular diseases.
- Cardiovascular disease is the most significant cause of morbidity and mortality in the western world and is rapidly becoming a primary cause of death worldwide.
- “Sarepta’s investment in LEXEO aligns with our vision of expanding the promise of gene therapy.